28442401|t|TRIB3 downregulation enhances doxorubicin - induced cytotoxicity in gastric cancer cells
28442401|a|TRIB3, which is a pseudokinase known to regulate multiple pro-survival pathways, appears to be a potential therapeutic target for the treatment of human tumors. However, its precise role in cancer is controversial, as TRIB3 protein levels have been associated with both good and poor prognosis in cancer patients. Here, we investigated the significance of TRIB3 expression in the survival of gastric cancer cells exposed to anticancer drugs. We found that the tested anticancer drug, doxorubicin, induced cytotoxicity by decreasing TRIB3 transcription, which was followed by apoptotic cell death. Moreover, TRIB3 siRNA knockdown appeared to enhance doxorubicin - induced apoptosis in gastric cancer cells, concurrently with altering the expression of downstream apoptotic factors. Conversely, overexpression of TRIB3 significantly protected cells against doxorubicin - induced apoptosis. Our results indicate that downregulation of TRIB3 appears to promote cell death and enhance doxorubicin - induced apoptosis, supporting the anti-apoptotic role of TRIB3. The inductions of three classes of MAPKs failed to affect doxorubicin -mediated TRIB3 downregulation, while TRIB3 overexpression did not affect doxorubicin - induced MAPK activation. In sum, our findings indicate that TRIB3 plays an anti-apoptotic role in doxorubicin -treated gastric cancer cell lines, perhaps indicating that the status of TRIB3 expression in response to anticancer drugs, such as doxorubicin, irinotecan or oxaliplatin, may reflect the efficiency for cancer therapy.
28442401	0	5	TRIB3	T103	UMLS:C1259051
28442401	6	20	downregulation	T038	UMLS:C0013081
28442401	30	41	doxorubicin	T103	UMLS:C0013089
28442401	52	64	cytotoxicity	T038	UMLS:C0596402
28442401	68	82	gastric cancer	T038	UMLS:C0024623
28442401	83	88	cells	T017	UMLS:C0334227
28442401	89	94	TRIB3	T103	UMLS:C1259051
28442401	107	119	pseudokinase	T103	UMLS:C0033684
28442401	129	168	regulate multiple pro-survival pathways	T038	UMLS:C1327622
28442401	196	207	therapeutic	T058	UMLS:C0087111
28442401	223	232	treatment	T058	UMLS:C0920425
28442401	236	241	human	T204	UMLS:C0086418
28442401	242	248	tumors	T038	UMLS:C0027651
28442401	279	285	cancer	T038	UMLS:C0006826
28442401	307	312	TRIB3	T103	UMLS:C1259051
28442401	313	327	protein levels	T033	UMLS:C0428479
28442401	359	363	good	T033	UMLS:C0278250
28442401	368	382	poor prognosis	T033	UMLS:C0278252
28442401	445	450	TRIB3	T103	UMLS:C1259051
28442401	451	461	expression	T038	UMLS:C1171362
28442401	469	477	survival	T038	UMLS:C0007620
28442401	481	495	gastric cancer	T038	UMLS:C0024623
28442401	496	501	cells	T017	UMLS:C0334227
28442401	513	529	anticancer drugs	T103	UMLS:C0003392
28442401	556	571	anticancer drug	T103	UMLS:C0003392
28442401	573	584	doxorubicin	T103	UMLS:C0013089
28442401	594	606	cytotoxicity	T038	UMLS:C0596402
28442401	621	626	TRIB3	T017	UMLS:C1540055
28442401	627	640	transcription	T038	UMLS:C0040649
28442401	664	684	apoptotic cell death	T038	UMLS:C0162638
28442401	696	707	TRIB3 siRNA	T103	UMLS:C1099354
28442401	708	717	knockdown	T062	UMLS:C2350567
28442401	738	749	doxorubicin	T103	UMLS:C0013089
28442401	760	769	apoptosis	T038	UMLS:C0162638
28442401	773	787	gastric cancer	T038	UMLS:C0024623
28442401	788	793	cells	T017	UMLS:C0334227
28442401	826	836	expression	T038	UMLS:C1171362
28442401	840	850	downstream	T082	UMLS:C0522506
28442401	851	868	apoptotic factors	T103	UMLS:C0763396
28442401	882	896	overexpression	T038	UMLS:C1514559
28442401	900	905	TRIB3	T103	UMLS:C1259051
28442401	920	935	protected cells	T017	UMLS:C0007634
28442401	944	955	doxorubicin	T103	UMLS:C0013089
28442401	966	975	apoptosis	T038	UMLS:C0162638
28442401	1003	1017	downregulation	T038	UMLS:C0013081
28442401	1021	1026	TRIB3	T103	UMLS:C1259051
28442401	1046	1056	cell death	T038	UMLS:C0007587
28442401	1069	1080	doxorubicin	T103	UMLS:C0013089
28442401	1091	1100	apoptosis	T038	UMLS:C0162638
28442401	1117	1131	anti-apoptotic	T103	UMLS:C2986514
28442401	1140	1145	TRIB3	T103	UMLS:C1259051
28442401	1151	1161	inductions	T038	UMLS:C0017391
28442401	1182	1187	MAPKs	T103	UMLS:C0752312
28442401	1205	1216	doxorubicin	T103	UMLS:C0013089
28442401	1227	1232	TRIB3	T103	UMLS:C1259051
28442401	1233	1247	downregulation	T038	UMLS:C0013081
28442401	1255	1260	TRIB3	T103	UMLS:C1259051
28442401	1261	1275	overexpression	T038	UMLS:C1514559
28442401	1291	1302	doxorubicin	T103	UMLS:C0013089
28442401	1313	1328	MAPK activation	T038	UMLS:C1155551
28442401	1342	1350	findings	T033	UMLS:C2825141
28442401	1365	1370	TRIB3	T103	UMLS:C1259051
28442401	1380	1394	anti-apoptotic	T103	UMLS:C2986514
28442401	1403	1414	doxorubicin	T103	UMLS:C0013089
28442401	1424	1438	gastric cancer	T038	UMLS:C0024623
28442401	1439	1449	cell lines	T017	UMLS:C0334227
28442401	1489	1494	TRIB3	T103	UMLS:C1259051
28442401	1495	1505	expression	T038	UMLS:C1171362
28442401	1521	1537	anticancer drugs	T103	UMLS:C0003392
28442401	1547	1558	doxorubicin	T103	UMLS:C0013089
28442401	1560	1570	irinotecan	T103	UMLS:C0123931
28442401	1574	1585	oxaliplatin	T103	UMLS:C0069717
28442401	1618	1632	cancer therapy	T058	UMLS:C0920425